Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAAKSHI KHATTRI

Allopathic & Osteopathic Physicians Dermatology

NPI
1265677033
CMS profile
1304956
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$371,070.07

438 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 5 of 9; records 201–250 of 438 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAAKSHI KHATTRI

NPI 1265677033 · CMS profile ID 1304956

Allopathic & Osteopathic Physicians / Dermatology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 9; records 201–250 of 438 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265677033?year=2022&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAAKSHI KHATTRI, NPI 1265677033, CMS profile ID 1304956. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 9; records 201–250 of 438 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265677033?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SAAKSHI KHATTRI, NPI 1265677033, CMS profile ID 1304956. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 9; records 201–250 of 438 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265677033?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SAAKSHI KHATTRI, NPI 1265677033, CMS profile ID 1304956, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 9; records 201–250 of 438 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1265677033?year=2022&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

438 matching records · $371,070.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 438 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 438.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LEO Pharma Inc. $273.6007/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936237021 CMS
LEO Pharma Inc. $178.0007/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936237027 CMS
ABBVIE INC. $575.0007/18/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061151 CMS
UCB, Inc. $1,420.0007/06/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038609277 CMS
ABBVIE INC. $1,725.0007/05/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061149 CMS
ABBVIE INC. $20.6606/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061147 CMS
Lilly USA, LLC $3,125.0006/30/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918318831 CMS
ABBVIE INC. $28.5606/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061145 CMS
ABBVIE INC. $1,725.0006/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061139 CMS
ABBVIE INC. $2,875.0006/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061141 CMS
ABBVIE INC. $6.7206/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061143 CMS
Lilly USA, LLC $2,200.0006/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918296891 CMS
Lilly USA, LLC $2,500.0006/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918339329 CMS
Janssen Scientific Affairs, LLC $1,250.0006/18/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887240161 CMS
ABBVIE INC. $118.7706/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061135 CMS
ABBVIE INC. $497.7806/16/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061137 CMS
Lilly USA, LLC $231.5906/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918280249 CMS
Lilly USA, LLC $142.5606/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918295429 CMS
Lilly USA, LLC $181.5506/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918296887 CMS
Lilly USA, LLC $122.2606/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918318819 CMS
Lilly USA, LLC $193.0806/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918326243 CMS
Lilly USA, LLC $143.2306/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918339325 CMS
Lilly USA, LLC $498.1806/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918361801 CMS
ABBVIE INC. $61.6806/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061131 CMS
ABBVIE INC. $5,175.0006/13/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061133 CMS
Janssen Biotech, Inc. $35.2206/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886276675 CMS
Lilly USA, LLC $1,250.0006/13/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918326247 CMS
ABBVIE INC. $160.5506/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061127 CMS
ABBVIE INC. $1,725.0006/08/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061129 CMS
ABBVIE INC. $2,875.0006/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061125 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $93.5306/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887784941 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $487.8106/07/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887784955 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $186.4506/07/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887784957 CMS
Janssen Scientific Affairs, LLC $71.2606/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887240175 CMS
ABBVIE INC. $185.6006/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061121 CMS
ABBVIE INC. $35.1406/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061123 CMS
ABBVIE INC. $124.5406/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061117 CMS
ABBVIE INC. $677.3006/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061119 CMS
Janssen Scientific Affairs, LLC $2,813.0005/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887240167 CMS
Janssen Scientific Affairs, LLC $4,375.0005/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887240199 CMS
Lilly USA, LLC $1,250.0005/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918295433 CMS
ABBVIE INC. $3.9605/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061115 CMS
Janssen Scientific Affairs, LLC $117.8705/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887240183 CMS
Janssen Scientific Affairs, LLC $2,550.8805/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887240191 CMS
ABBVIE INC. $71.7705/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061105 CMS
ABBVIE INC. $191.3505/24/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061107 CMS
ABBVIE INC. $1,725.0005/24/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061109 CMS
ABBVIE INC. $1,725.0005/24/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061111 CMS
ABBVIE INC. $1,725.0005/24/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061113 CMS
ABBVIE INC. $26.1305/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893061103 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $20,125.62 65
PY2020 $46,079.35 57
PY2021 $163,889.74 175
PY2022 $371,070.07 438
PY2023 $452,423.07 452
PY2024 $686,765.40 595
PY2025 $692,693.50 551

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $451,392.98 155
PY2024 Principal investigator $9,724,584.84 263
PY2023 Recipient $3,200.00 1
PY2023 Principal investigator $1,915,390.66 56
PY2022 Recipient $17,686.85 2
PY2022 Principal investigator $332,040.88 24
PY2021 Principal investigator $390,424.71 28
PY2020 Recipient $5,200.00 1
PY2020 Principal investigator $116,617.20 16

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

155 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,484.10 12/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240477409
Principal investigator 1 Incyte Corporation $6,846.60 12/08/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560508
Principal investigator 1 Incyte Corporation $52.14 12/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477414
Principal investigator 1 Incyte Corporation $35.55 12/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477430
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477435
Principal investigator 1 Incyte Corporation $14.22 12/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477439
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477443
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477447
Principal investigator 1 Incyte Corporation $11.85 12/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477460
Principal investigator 1 Incyte Corporation $11.85 12/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477464
Principal investigator 1 Incyte Corporation $1,777.00 11/24/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560490
Principal investigator 1 Incyte Corporation $1,256.90 11/24/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560503
Principal investigator 1 Incyte Corporation $2,349.90 11/12/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560497
Principal investigator 1 Incyte Corporation $20,250.00 11/07/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560476
Principal investigator 1 Incyte Corporation $7,000.00 11/07/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560480
Principal investigator 1 Incyte Corporation $114.50 11/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477419
Principal investigator 1 Incyte Corporation $62.27 11/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477422
Principal investigator 1 Incyte Corporation $54.76 11/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477427
Principal investigator 1 Incyte Corporation $59.13 11/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477455
Principal investigator 1 ABBVIE INC. $8,348.00 10/21/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MED AT MT SINAI
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202517557
Principal investigator 1 ABBVIE INC. $8,348.00 10/21/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MED AT MT SINAI
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202517559
Principal investigator 1 Incyte Corporation $1,777.00 10/20/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560486
Principal investigator 1 Incyte Corporation $93.60 10/20/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560531
Principal investigator 1 Incyte Corporation $2,489.00 10/20/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560539
Principal investigator 1 Incyte Corporation $1,115.80 10/02/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560513
Principal investigator 1 Incyte Corporation $1,594.00 10/02/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560518
Principal investigator 1 Incyte Corporation $1,594.00 10/02/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560524
Principal investigator 1 Incyte Corporation $109.52 10/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477451
Principal investigator 1 Incyte Corporation $1,556.10 09/10/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560470
Principal investigator 1 Incyte Corporation $1,157.60 08/20/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560428
Principal investigator 1 Incyte Corporation $1,594.00 08/20/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560433
Principal investigator 1 Incyte Corporation $2,823.00 08/20/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560465
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,202.20 08/15/2025 Covered Recipient Teaching Hospital
MOUNT SINAI HOSPITAL
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223268156
Principal investigator 1 Incyte Corporation $1,295.00 08/01/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560438
Principal investigator 1 Incyte Corporation $2,611.00 08/01/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560444
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $101.25 07/23/2025 Covered Recipient Teaching Hospital
MOUNT SINAI HOSPITAL
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223268152
Principal investigator 1 Incyte Corporation $1,127.90 07/18/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560450
Principal investigator 1 Incyte Corporation $2,489.00 07/18/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560455
Principal investigator 1 Incyte Corporation $578.00 07/18/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560459
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,720.64 07/09/2025 Covered Recipient Teaching Hospital
MOUNT SINAI HOSPITAL
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223268150
Principal investigator 1 Incyte Corporation $1,594.00 06/25/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560366
Principal investigator 1 Incyte Corporation $1,777.00 06/25/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560373
Principal investigator 1 Incyte Corporation $1,594.00 06/25/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560392
Principal investigator 1 Incyte Corporation $1,743.60 06/25/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560400
Principal investigator 1 Incyte Corporation $1,729.00 06/11/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560381
Principal investigator 1 Incyte Corporation $2,611.00 06/11/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560387
Principal investigator 1 Incyte Corporation $1,122.10 06/11/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560413
Principal investigator 1 Incyte Corporation $6.18 06/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477302
Principal investigator 1 Incyte Corporation $31.93 06/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477356
Principal investigator 1 Incyte Corporation $32.88 06/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477361
Principal investigator 1 Incyte Corporation $64.72 06/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477365
Principal investigator 1 Incyte Corporation $217.55 06/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477369
Principal investigator 1 Incyte Corporation $8.48 06/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477382
Principal investigator 1 Incyte Corporation $32.88 06/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477386
Principal investigator 1 Incyte Corporation $32.88 06/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477390
Principal investigator 1 Incyte Corporation $32.88 06/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477394
Principal investigator 1 Incyte Corporation $2,240.10 05/21/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560417
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,432.85 05/21/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280070
Principal investigator 1 Incyte Corporation $425.00 05/12/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560405
Principal investigator 1 Incyte Corporation $750.00 05/12/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560410
Principal investigator 1 Incyte Corporation $59.13 05/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477332
Principal investigator 1 Incyte Corporation $19.44 05/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477336
Principal investigator 1 Incyte Corporation $34.35 05/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477341
Principal investigator 1 Incyte Corporation $124.54 05/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477345
Principal investigator 1 Incyte Corporation $80.90 05/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477353
Principal investigator 1 Incyte Corporation $68.70 05/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477378
Principal investigator 1 Incyte Corporation $1,594.00 05/02/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560344
Principal investigator 1 Incyte Corporation $1,383.20 05/02/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560351
Principal investigator 1 Incyte Corporation $1,439.90 05/02/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560359
Principal investigator 1 Incyte Corporation $1,729.00 05/02/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560422
Principal investigator 1 Incyte Corporation $1,295.00 04/09/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560318
Principal investigator 1 Incyte Corporation $2,611.00 04/09/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560337
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,170.86 04/09/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277752
Principal investigator 1 Incyte Corporation $34.35 04/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477306
Principal investigator 1 Incyte Corporation $26.73 04/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477311
Principal investigator 1 Incyte Corporation $31.93 04/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477316
Principal investigator 1 Incyte Corporation $0.93 04/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477319
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477324
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477328
Principal investigator 1 Incyte Corporation $74.04 04/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477349
Principal investigator 1 Incyte Corporation $80.90 04/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477373
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477397
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477402
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477406
Principal investigator 1 Incyte Corporation $1,777.00 04/02/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560314
Principal investigator 1 Incyte Corporation $578.00 04/02/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560325
Principal investigator 1 Incyte Corporation $1,199.10 04/02/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560333
Principal investigator 1 Incyte Corporation $2,611.00 03/12/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560222
Principal investigator 1 Incyte Corporation $1,952.00 03/12/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560229
Principal investigator 1 Incyte Corporation $748.60 03/12/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560251
Principal investigator 1 Incyte Corporation $1,783.00 03/12/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560270
Principal investigator 1 Incyte Corporation $1,109.90 03/12/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560295
Principal investigator 1 Incyte Corporation $270.80 03/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477232
Principal investigator 1 Incyte Corporation $240.45 03/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477257
Principal investigator 1 Incyte Corporation $186.81 03/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477264
Principal investigator 1 Incyte Corporation $1,777.00 03/03/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560234
Principal investigator 1 Incyte Corporation $2,823.00 03/03/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560239
Principal investigator 1 Incyte Corporation $1,011.60 03/03/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560244
Principal investigator 1 Incyte Corporation $1,594.00 03/03/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560258
Principal investigator 1 Incyte Corporation $1,777.00 03/03/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560288
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,791.94 03/03/2025 Covered Recipient Teaching Hospital
MOUNT SINAI HOSPITAL
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223268138
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,881.92 02/14/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235995603
Principal investigator 1 Incyte Corporation $1,729.00 02/10/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560207
Principal investigator 1 Incyte Corporation $2,611.00 02/10/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560211
Principal investigator 1 Incyte Corporation $1,851.00 02/10/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560217
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,030.93 02/03/2025 Covered Recipient Teaching Hospital
MOUNT SINAI HOSPITAL
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223268136
Principal investigator 1 AstraZeneca UK Limited $86,061.16 01/27/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Multicenter Randomized Double blind Placebo controlled Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus and Refractory and/or Intolerant to Antimalarial Therapy No dispute reported 06/30/2026 1185540850
Principal investigator 1 Incyte Corporation $1,594.00 01/27/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560178
Principal investigator 1 Incyte Corporation $1,777.00 01/27/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560180
Principal investigator 1 Incyte Corporation $1,777.00 01/27/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560185
Principal investigator 1 Incyte Corporation $578.00 01/27/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560264
Principal investigator 1 Incyte Corporation $1,594.00 01/27/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560302
Principal investigator 1 Incyte Corporation $286.70 01/15/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560140
Principal investigator 1 Incyte Corporation $2,811.00 01/15/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560146
Principal investigator 1 Incyte Corporation $1,862.00 01/15/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560152
Principal investigator 1 Incyte Corporation $1,952.00 01/15/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560157
Principal investigator 1 Incyte Corporation $2,611.00 01/15/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560162
Principal investigator 1 Incyte Corporation $1,594.00 01/15/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560167
Principal investigator 1 Incyte Corporation $578.00 01/15/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560173
Principal investigator 1 Incyte Corporation $276.40 01/15/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560191
Principal investigator 1 Incyte Corporation $1,777.00 01/15/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560200
Principal investigator 1 Incyte Corporation $1,729.00 01/15/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560276
Principal investigator 1 Incyte Corporation $1,729.00 01/15/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560282
Principal investigator 1 Incyte Corporation $1,777.00 01/15/2025 Non-covered Recipient Entity
MOUNT SINAI DOCTORS
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240560306
Principal investigator 1 Amgen Inc. $140,903.31 01/02/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies No dispute reported 06/30/2026 1246642447
Principal investigator 1 Incyte Corporation $79.50 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477162
Principal investigator 1 Incyte Corporation $90.10 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477168
Principal investigator 1 Incyte Corporation $121.90 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477172
Principal investigator 1 Incyte Corporation $84.80 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477177
Principal investigator 1 Incyte Corporation $206.70 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477181
Principal investigator 1 Incyte Corporation $106.00 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477185
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477190
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477194
Principal investigator 1 Incyte Corporation $37.10 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477198
Principal investigator 1 Incyte Corporation $32.28 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477202
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477206
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477211
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477215
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477219
Principal investigator 1 Incyte Corporation $74.20 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477221
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477224
Principal investigator 1 Incyte Corporation $114.50 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477228
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477237
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477240
Principal investigator 1 Incyte Corporation $109.52 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477244
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477248
Principal investigator 1 Incyte Corporation $15.90 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477253
Principal investigator 1 Incyte Corporation $124.54 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477261
Principal investigator 1 Incyte Corporation $62.27 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477269
Principal investigator 1 Incyte Corporation $201.40 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477274
Principal investigator 1 Incyte Corporation $37.66 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477281
Principal investigator 1 Incyte Corporation $37.66 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477285
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477290
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477294
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240477298